In breast cancer, a YTHDF2-dependent mechanism underlies the degradation of the BCL2 interacting protein 3 (BNIP3) mRNA, which would otherwise encode an apoptosis-promoting protein that is a downstream target of FTO-mediated m6A modifications [62]. Here, FTO is linked to breast carcinoma.